Pradefovir meets Phase IIb HBV endpoint

Metabasis (MBRX) said pradefovir mesylate met the primary endpoint of reducing serum HBV DNA levels in a Phase IIb trial. The open-label, international trial in 242 patients compared four doses of pra...